nach oben

Endocrine

Erschienen in:

01.08.2020 | Meta-Analysis

Meta-analysis of metabolic changes in children with idiopathic growth hormone deficiency after recombinant human growth hormone replacement therapy

verfasst von: Yuan Yuan, Bo Zhou, Shufang Liu, Yunfeng Wang, Kundi Wang, Zhixin Zhang, Wenquan Niu

Erschienen in: Endocrine | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purposes

We aimed to assess the effects of recombinant human growth hormone (rhGH) replacement therapy on metabolic changes by synthesizing data from clinical trials involving children with idiopathic growth hormone deficiency (IGHD).

Methods

Two investigators independently completed literature search, quality assessment, and data extraction. Effect-size estimates are expressed as weighted mean difference (WMD) with 95% confidence interval (CI).

Results

A total of 16 clinical trials involving 1319 children were eligible for analysis. Overall analyses showed that total cholesterol was significantly decreased after rhGH replacement therapy (WMD: −0.20 mmol/l; 95% CI: −0.30 to −0.10; p < 0.001), and high-density lipoprotein was significantly increased (WMD: 0.29 mmol/l; 95% CI: 0.24 to 0.33; p < 0.001). Marginal increase was noted for low-density lipoprotein (WMD: −0.22 mmol/l; 95% CI: −0.47 to 0.22; p = 0.092). Subsidiary and meta-regression analyses revealed that length of intervention and sample size were possible causes of heterogeneity. There was a low probability of publication bias.

Conclusions

Our findings indicate an obviously favorable role of rhGH replacement therapy in lipid metabolism in children with IGHD, and this role might be dependent on length of intervention.

Nur mit Berechtigung zugänglich

X.L. Bao, Y.F. Shi, Y.C. Du, R. Liu, J.Y. Deng, S.M. Gao, Prevalence of growth hormone deficiency of children in Beijing. Chin. Med. J. 105(5), 401–405 (1992)PubMed

A. Chinoy, P.G. Murray, Diagnosis of growth hormone deficiency in the paediatric and transitional age. Best Pract. Res. Clin. Endocrinol. Metab. 30(6), 737–747 (2016). https://doi.org/10.1016/j.beem.2016.11.002CrossRefPubMed

R.C. Lindsey, S. Mohan, Skeletal effects of growth hormone and insulin-like growth factor-I therapy. Mol. Cell Endocrinol. 432, 44–55 (2016). https://doi.org/10.1016/j.mce.2015.09.017CrossRefPubMed

D. Capalbo, A. Esposito, R. Di Mase, F. Barbieri, G. Parenti, P. Vajro, C. Pignata, M. Salerno, Update on early cardiovascular and metabolic risk factors in children and adolescents affected with growth hormone deficiency. Minerva Endocrinol. 37(4), 379–389 (2012)PubMed

D. Capalbo, F. Barbieri, N. Improda, F. Giallauria, E. Di Pietro, A. Rapacciuolo, R. Di Mase, C. Vigorito, M. Salerno, Growth hormone improves cardiopulmonary capacity and body composition in children with growth hormone deficiency. J. Clin. Endocrinol. Metab. 102(11), 4080–4088 (2017). https://doi.org/10.1210/jc.2017-00871CrossRefPubMed

J.H. Quitmann, A.C. Rohenkohl, U. Kammerer, C. Schofl, M. Bullinger, H.G. Dorr, [Quality of life of young adults after a growth hormone therapy with childhood onset]. Dtsch. Med. Wochenschr. 139(46), 2335–2338 (2014). https://doi.org/10.1055/s-0034-1387314CrossRefPubMed

R. Lanes, Cardiovascular risk in growth hormone deficiency: beneficial effects of growth hormone replacement therapy. Endocrinol. Metab. Clin. North. Am. 45(2), 405–418 (2016). https://doi.org/10.1016/j.ecl.2016.01.005CrossRefPubMed

G. Saggese, M.B. Ranke, P. Saenger, R.G. Rosenfeld, T. Tanaka, J.L. Chaussain, M.O. Savage, Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Ten years after the Availability of Recombinant Human Growth Hormone Workshop held in Pisa, Italy, 27-28 March 1998. Horm. Res. 50(6), 320–340 (1998). https://doi.org/10.1159/000023298CrossRefPubMed

C. De Leonibus, S. De Marco, A. Stevens, P. Clayton, F. Chiarelli, A. Mohn, Growth hormone deficiency in prepubertal children: predictive markers of cardiovascular disease. Horm. Res. Paediatr. 85(6), 363–371 (2016). https://doi.org/10.1159/000444143CrossRefPubMed

10.

F. Prodam, P. Marzullo, G. Aimaretti, Growth hormone deficiency in children. Best Pract. Res. Clin. Endocrinol. Metab. 30(6), 677–678 (2016). https://doi.org/10.1016/j.beem.2016.12.001CrossRefPubMed

11.

S.R. Daniels, F.R. Greer; Committee on Nutrition, Lipid screening and cardiovascular health in childhood. Pediatrics 122(1), 198–208 (2008). https://doi.org/10.1542/peds.2008-1349CrossRefPubMed

12.

A. Pires, C. Sena, R. Seica, Dyslipidemia and cardiovascular changes in children. Curr. Opin. Cardiol. 31(1), 95–100 (2016). https://doi.org/10.1097/HCO.0000000000000249CrossRefPubMed

13.

J. Rothermel, C. Knop, N. Lass, C. Toschke, R. Wunsch, T. Reinehr, Carotid intima-media thickness in children treated with growth hormone: a follow-up study over three years. Horm. Res. Paediatr. 87(2), 73–80 (2017). https://doi.org/10.1159/000450643CrossRefPubMed

14.

M. Chen, D. Gan, Y. Luo, S. Rampersad, L. Xu, S. Yang, N. Li, H. Li, Effect of recombinant human growth hormone therapy on blood lipid and carotid intima-media thickness in children with growth hormone deficiency. Pediatr. Res. 83(5), 954–960 (2018). https://doi.org/10.1038/pr.2017.271CrossRefPubMedPubMedCentral

15.

M. Crowther, W. Lim, M.A. Crowther, Systematic review and meta-analysis methodology. Blood 116(17), 3140–3146 (2010). https://doi.org/10.1182/blood-2010-05-280883CrossRefPubMed

16.

K. Slim, E. Nini, D. Forestier, F. Kwiatkowski, Y. Panis, J. Chipponi, Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J. Surg. 73(9), 712–716 (2003)CrossRef

17.

S. Duval, R. Tweedie, Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2), 455–463 (2000). https://doi.org/10.1111/j.0006-341x.2000.00455.xCrossRefPubMed

18.

W. Lu, S. Shen, X. Luo, C. Gong, X. Gu, Y. Li, M. Du, R. Jin, Q. Zhou, W. Wang, Comparative evaluation of short-term biomarker response to treatment for growth hormone deficiency in Chinese children with growth hormone deficiency born small for or appropriate for gestational age: a randomized phase IV open-label study. Ther. Adv. Endocrinol. Metab. 4(2), 41–49 (2013). https://doi.org/10.1177/2042018813484051CrossRefPubMedPubMedCentral

19.

A. Ciresi, F. Ciccio, S. Radellini, V. Guarnotta, A.M. Calcaterra, C. Giordano, More favorable metabolic impact of three-times-weekly versus daily growth hormone treatment in naive GH-deficient children. Int. J. Endocrinol. 2017, 8469680 (2017). https://doi.org/10.1155/2017/8469680CrossRefPubMedPubMedCentral

20.

X. Luo, L. Hou, L. Liang, G. Dong, S. Shen, Z. Zhao, C.X. Gong, Y. Li, M.L. Du, Z. Su, H. Du, C. Yan, Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur. J. Endocrinol. 177(2), 195–205 (2017). https://doi.org/10.1530/EJE-16-0905CrossRefPubMedPubMedCentral

21.

C. Foster, A. Burton, J. Scholl, M.L. Scott, V. Gunter, K. McCormick, Lipid patterns in treated growth hormone deficient children vs. short stature controls. J. Pediatr. Endocrinol. Metab. 27(9–10), 909–914 (2014). https://doi.org/10.1515/jpem-2013-0488CrossRefPubMed

22.

E.O. Reiter, K.M. Attie, T. Moshang Jr., B.L. Silverman, S.F. Kemp, R.B. Neuwirth, K.M. Ford, P. Saenger, Genentech IAICSG, A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. J. Clin. Endocrinol. Metab. 86(10), 4700–4706 (2001). https://doi.org/10.1210/jcem.86.10.7932CrossRefPubMed

23.

N. Mauras, K.M. Attie, E.O. Reiter, P. Saenger, J. Baptista, High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J. Clin. Endocrinol. Metab. 85(10), 3653–3660 (2000). https://doi.org/10.1210/jcem.85.10.6906CrossRefPubMed

24.

P. Cohen, J. Germak, A.D. Rogol, W. Weng, A.M. Kappelgaard, R.G. Rosenfeld; American Norditropin Study Group, Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J. Clin. Endocrinol. Metab. 95(5), 2089–2098 (2010). https://doi.org/10.1210/jc.2009-2139CrossRefPubMed

25.

Y. Xue, Y. Gao, S. Wang, P. Wang, An examination of the effects of different doses of recombinant human growth hormone on children with growth hormone deficiency. Exp. Ther. Med. 11(5), 1647–1652 (2016). https://doi.org/10.3892/etm.2016.3091CrossRefPubMedPubMedCentral

26.

A. Ciresi, S. Radellini, V. Guarnotta, M.G. Mineo, C. Giordano, The metabolic outcomes of growth hormone treatment in children are gender specific. Endocr. Connect. 7(7), 879–887 (2018). https://doi.org/10.1530/EC-18-0135CrossRefPubMedPubMedCentral

27.

F. Peter, M. Bidlingmaier, C. Savoy, H.J. Ji, P.H. Saenger, Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J. Clin. Endocrinol. Metab. 97(2), 400–407 (2012). https://doi.org/10.1210/jc.2011-2234CrossRefPubMed

28.

G. Radetti, F. Buzi, C. Paganini, C. Martelli, S. Adami, A four year dose-response study of recombinant human growth hormone treatment of growth hormone deficient children: effects on growth, bone growth and bone mineralization. Eur. J. Endocrinol. 142(1), 42–46 (2000). https://doi.org/10.1530/eje.0.1420042CrossRefPubMed

29.

W.V. Moore, H.J. Nguyen, G.B. Kletter, B.S. Miller, D. Rogers, D. Ng, J.A. Moore, E. Humphriss, J.L. Cleland, G.M. Bright, A. Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency. J. Clin. Endocrinol. Metab. 101(3), 1091–1097 (2016). https://doi.org/10.1210/jc.2015-3279CrossRefPubMed

30.

M. Rudling, G. Norstedt, H. Olivecrona, E. Reihner, J.A. Gustafsson, B. Angelin, Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc. Natl Acad. Sci. USA 89(15), 6983–6987 (1992). https://doi.org/10.1073/pnas.89.15.6983CrossRefPubMed

31.

H. Olivecrona, S. Ericsson, B. Angelin, Growth hormone treatment does not alter biliary lipid metabolism in healthy adult men. J. Clin. Endocrinol. Metab. 80(4), 1113–1117 (1995). https://doi.org/10.1210/jcem.80.4.7714078CrossRefPubMed

32.

S. Eden, O. Wiklund, J. Oscarsson, T. Rosen, B.A. Bengtsson, Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler. Thromb. 13(2), 296–301 (1993). https://doi.org/10.1161/01.atv.13.2.296CrossRefPubMed

33.

S. Lind, M. Rudling, S. Ericsson, H. Olivecrona, M. Eriksson, B. Borgstrom, G. Eggertsen, L. Berglund, B. Angelin, Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arterioscler. Thromb. Vasc. Biol. 24(2), 349–356 (2004). https://doi.org/10.1161/01.ATV.0000110657.67317.90CrossRefPubMed

34.

A.M. Mahmoud, R.J. Hernandez Bautista, M.A. Sandhu, O.E. Hussein, Beneficial effects of citrus flavonoids on cardiovascular and metabolic health. Oxid. Med. Cell. Longev. 2019, 5484138 (2019). https://doi.org/10.1155/2019/5484138CrossRefPubMedPubMedCentral

35.

O. Guardamagna, F. Abello, G. Anfossi, M. Pirro, Lipoprotein(a) and family history of cardiovascular disease in children with familial dyslipidemias. J. Pediatr. 159(2), 314–319 (2011). https://doi.org/10.1016/j.jpeds.2011.01.038CrossRefPubMed

36.

Z. Quijada, M. Paoli, Y. Zerpa, N. Camacho, R. Cichetti, V. Villarroel, G. Arata-Bellabarba, R. Lanes, The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors. Pediatr. Diabetes 9(5), 464–471 (2008). https://doi.org/10.1111/j.1399-5448.2008.00406.xCrossRefPubMed

37.

D. Capalbo, A. Lo Vecchio, V. Farina, L. Spinelli, A. Palladino, C. Tiano, T. Lettiero, G. Lombardi, A. Colao, M. Salerno, Subtle alterations of cardiac performance in children with growth hormone deficiency: results of a two-year prospective, case-control study. J. Clin. Endocrinol. Metab. 94(9), 3347–3355 (2009). https://doi.org/10.1210/jc.2008-2639CrossRefPubMed

38.

E. Gomez-Guzman, M.D. Canete, R. Valle-Martos, R. Canete, M. Valle, L. Jimenez-Reina, J. Caballero-Villarraso, Short-term evaluation of left ventricular mass and function in children with growth hormone deficiency after replacement treatment. Front. Pediatr. 6, 174 (2018). https://doi.org/10.3389/fped.2018.00174CrossRefPubMedPubMedCentral

39.

C. Azzarito, L. Boiardi, M. Zini, A. Agosti, M. Biacchessi, R. Biagi, I. Portioli, Short and long-term effects of growth hormone treatment on lipid, lipoprotein, and apolipoprotein levels in short normal children. Horm. Metab. Res. 26(9), 432–435 (1994). https://doi.org/10.1055/s-2007-1001724CrossRefPubMed

40.

K.A. Metwalley, H.S. Farghaly, H.A. Abd El-Hafeez, Evaluation of left ventricular mass and function, lipid profile, and insulin resistance in Egyptian children with growth hormone deficiency: a single-center prospective case-control study. Indian J. Endocrinol. Metab. 17(5), 876–882 (2013). https://doi.org/10.4103/2230-8210.117234CrossRefPubMedPubMedCentral

41.

C.J. Child, A.G. Zimmermann, R.S. Scott, G.B. Cutler Jr., T. Battelino, W.F. Blum; GeNe SISIAB, Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program. J. Clin. Endocrinol. Metab. 96(6), E1025–E1034 (2011). https://doi.org/10.1210/jc.2010-3023CrossRefPubMed

42.

F. Baronio, L. Mazzanti, Y. Girtler, F. Tamburrino, A. Fazzi, F. Lupi, S. Longhi, G. Radetti, The influence of growth hormone treatment on glucose homeostasis in growthhormone-deficient children: a six-year follow-up study. Horm. Res. Paediatr. 86(3), 196–200 (2016). https://doi.org/10.1159/000448841CrossRefPubMed

Titel: Meta-analysis of metabolic changes in children with idiopathic growth hormone deficiency after recombinant human growth hormone replacement therapy
verfasst von: Yuan Yuan
Bo Zhou
Shufang Liu
Yunfeng Wang
Kundi Wang
Zhixin Zhang
Wenquan Niu
Publikationsdatum: 01.08.2020
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2021
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02435-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Meta-analysis of metabolic changes in children with idiopathic growth hormone deficiency after recombinant human growth hormone replacement therapy

Abstract

Purposes

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purposes

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated anti‑TSHR immunoassay for Graves’ disease: a Chinese multicenter study

Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations

Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic

Growth plate gene involment and isolated short stature

Die Rolle der Androgene bei SARS-CoV-2-Infektion

The validity of cost-effectiveness analyses of tight glycemic control. A systematic survey of economic evaluations of pharmacological interventions in patients with type 2 diabetes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin